The correct name for selegiline is selegiline phosphate tablets. It is an oral antihyperglycemic agent of selegiline dipeptidyl peptidase 4 inhibitor, which improves blood glucose by increasing the level of active enteric insulinotropic hormone. Side effects of selegiline hydrochloride tablets include upper respiratory tract infection, nasopharyngitis, constipation, vomiting, headache, arthralgia, muscular pain, limb pain, and back pain. This product may be used alone or in combination with metformin to improve glycemic control in patients with type 2 diabetes. Serious hypersensitivity reactions, including anaphylactic reactions, angioedema, rash, urticaria, cutaneous vasculitis, and exfoliative skin damage; or acute pancreatitis, including hemorrhagic or necrotizing pancreatitis, elevated liver enzymes, pancreatitis, and renal hypoplasia, have occurred after administration. It is contraindicated in patients who are allergic to any of the ingredients of selegiline hydrochloride tablets, this product should not be used in patients with type 1 diabetes mellitus or in the treatment of diabetic ketoacidosis, and it is not suitable for use in lactating women. If you need to use this product, please consult a professional doctor, follow the doctor’s instructions, reasonable use of medication.